januvia 50 mg
orifarm as - sitagliptinfosfatmonohydrat - tablett, filmdrasjert - 50 mg
almogran 12.5 mg
almirall, s.a. - almotriptanmalat - tablett, filmdrasjert - 12.5 mg
hydroxyzine bluefish 25 mg
bluefish pharmaceuticals ab - hydroksyzinhydroklorid - tablett, filmdrasjert - 25 mg
hydroxyzine bluefish 10 mg
bluefish pharmaceuticals ab - hydroksyzinhydroklorid - tablett, filmdrasjert - 10 mg
losartan medical valley 100 mg
medical valley invest ab - losartankalium - tablett, filmdrasjert - 100 mg
losartan medical valley 12.5 mg
medical valley invest ab - losartankalium - tablett, filmdrasjert - 12.5 mg
losartan medical valley 50 mg
medical valley invest ab - losartankalium - tablett, filmdrasjert - 50 mg
femoston 2 mg / 10 mg
viatris healthcare ltd. - Østradiolhemihydrat / dydrogesteron - tablett, filmdrasjert - 2 mg / 10 mg
vidaza
bristol-myers squibb pharma eeig - azacitidin - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastiske midler - vidaza is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with: intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification. vidaza is indicated for the treatment of adult patients aged 65 years or older who are not eligible for hsct with aml with >30% marrow blasts according to the who classification.
azacitidine celgene
celgene europe bv - azacitidin - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastiske midler - azacitidine celgene is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification,aml with >30% marrow blasts according to the who classification.